Cancer du poumon à petites cellules · ligne 2 · Tarlatamab — SCLC à 2L+ en phase extensive (DeLLphi-301; DLL3 × CD3 BiTE)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Ligne thérapeutique | 2 |
|---|---|
| Voie | agressif |
| Régime lié | REG-TARLATAMAB |
| ID | IND-SCLC-RR-TARLATAMAB |
|---|---|
| Type | Indication |
| État | reviewed 2026-05-08 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-SCLC |
| Sources | SRC-DELLPHI-301-AHN-2023 SRC-ESMO-SCLC-2021 SRC-NCCN-SCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for R/R ES-SCLC after platinum-based 1L chemotherapy. No biomarker dependency for label use (DLL3 IHC NOT required); applicability driven by line-of-therapy + ECOG + organ function + access to inpatient infusion centre. Mandatory cycle 1 inpatient monitoring (≥22 hr post D1 + D8) + tocilizumab-on-formulary + ICU access for Grade ≥3 CRS are structural deployment constraints beyond drug acquisition cost. Ukraine access constraint dominant (not registered, not НСЗУ; out-of-pocket USD 30-40K/cycle) AND structural infrastructure barrier limits realistic deployment. Evidence level: moderate (single-arm phase 2 + FDA accelerated approval; phase 3 DeLLphi-304 confirmatory trial pending); strength of recommendation: conditional. Algorithm wiring deferred — SCLC R/R algorithm not yet authored in KB; out of chunk scope. PUL-A4 chunk closes #491.
Utilisé par
Algorithmes
ALGO-SCLC-2L- ALGO-SCLC-2L